307 related articles for article (PubMed ID: 28720391)
1. Recommendations for the Management of Rare Kidney Cancers.
Giles RH; Choueiri TK; Heng DY; Albiges L; Hsieh JJ; Linehan WM; Pal S; Maskens D; Paseman B; Jonasch E; Malouf G; Molina AM; Pickering L; Shuch B; Srinivas S; Srinivasan R; Tannir NM; Bex A
Eur Urol; 2017 Dec; 72(6):974-983. PubMed ID: 28720391
[TBL] [Abstract][Full Text] [Related]
2. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
[TBL] [Abstract][Full Text] [Related]
3. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
4. Management of non-clear cell renal cell carcinoma: Current approaches.
Tsimafeyeu I
Urol Oncol; 2017 Jan; 35(1):5-13. PubMed ID: 27544302
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies for non-clear renal cell carcinoma.
Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
[TBL] [Abstract][Full Text] [Related]
6. Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
Flippot R; Damarla V; McGregor BA
Urol Clin North Am; 2020 Aug; 47(3):319-327. PubMed ID: 32600534
[TBL] [Abstract][Full Text] [Related]
7. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
Harshman LC; Choueiri TK
Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
[TBL] [Abstract][Full Text] [Related]
8. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for variant renal cancer: a true orphan disease.
Stadler WM
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6393S-6S. PubMed ID: 15448037
[TBL] [Abstract][Full Text] [Related]
10. The current management of renal cell carcinoma.
Kuusk T; Grivas N; de Bruijn R; Bex A
Minerva Med; 2017 Aug; 108(4):357-369. PubMed ID: 28176516
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
12. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
[TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on renal cell carcinoma: 2014 update.
Ljungberg B; Bensalah K; Canfield S; Dabestani S; Hofmann F; Hora M; Kuczyk MA; Lam T; Marconi L; Merseburger AS; Mulders P; Powles T; Staehler M; Volpe A; Bex A
Eur Urol; 2015 May; 67(5):913-24. PubMed ID: 25616710
[TBL] [Abstract][Full Text] [Related]
14. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
15. Advanced treatments in non-clear renal cell carcinoma.
Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Strategies for Hereditary Kidney Cancer.
Sidana A; Srinivasan R
Curr Oncol Rep; 2016 Aug; 18(8):50. PubMed ID: 27325049
[TBL] [Abstract][Full Text] [Related]
17. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
Shinohara N; Abe T
Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
Westerman ME; Shapiro DD; Wood CG; Karam JA
Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
[TBL] [Abstract][Full Text] [Related]
20. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
Malouf GG; Joseph RW; Shah AY; Tannir NM
Clin Adv Hematol Oncol; 2017 May; 15(5):409-418. PubMed ID: 28591094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
